1 Evaluation of high-throughput SARS-CoV-2 serological assays in

2 a longitudinal cohort of mild COVID-19 patients: sensitivity,

3 specificity and association with virus neutralization test

Antonin Bal^{1,2}, Bruno Pozzetto^{3,4}, Mary-Anne Trabaud¹, Vanessa Escuret^{1,2}, Muriel
Rabilloud^{5,6}, Carole Langlois-Jacques^{5,6}, Adèle Paul^{7,8}, Nicolas Guibert^{7,8}, Constance
D'Aubarede^{7,8}, Amélie Massardier-Pilonchery^{7,8}, André Boibieux⁹, Florence Morfin^{1,2},
Virginie Pitiot⁸, François Gueyffier^{6,10}, Bruno Lina^{1,2}, Jean-Baptiste Fassier^{7,8}, Sophie
Trouillet-Assant^{,2} COVID SER STUDY GROUP

- 9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
- National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,
 France
- ¹² ² CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,
- 13 U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon,
- 14 France
- ¹⁵ ³GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean
- 16 Monnet, Lyon University, Saint-Etienne, France
- ⁴Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint Etienne, France
- ⁵Université de Lyon, F-69000, Lyon, France; Université Lyon 1, F-69100, Villeurbanne,
- France; Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et
 Bioinformatique, F-69003, Lyon, France
- ⁶ CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
 Equipe Biostatistique-Santé, 69100, Villeurbanne, France.
- ⁷ Lyon University, Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, 8
- 25 avenue Rockefeller Lyon, France
- ⁸ Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
- ⁹ Infectious Diseases Department, Hospices Civils de Lyon, Lyon, France.
- ¹⁰Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
- 29
- 30 Corresponding author: Dr Sophie Trouillet-Assant, Ph.D
- 31 Hospices Civils de Lyon, France
- 32 Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,U1111,
- 33 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France
- 34 Phone: + 33 (0)472678780 Email: sophie.assant@chu-lyon.fr
- 35 Keywords: COVID-19; SARS-CoV-2; Serological assays; Virus neutralization; Health-care
- 36 workers

It is made available under a CC-BY-NC-ND 4.0 International license .

Objectives: We evaluated widely-used SARS-CoV-2 serological tests and their potential
association with virus neutralization test (VNT) in a cohort of mild COVID-19 patients.

Methods: A total of 439 specimens were longitudinally collected from 76 healthcare workers with RT-PCR-confirmed mild COVID-19. Nine serological assays developed by leading global companies (Abbott, DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun) were assessed. For each test the sensitivity to detect SARS-CoV-2 antibodies was determined weekly after symptom onset. Correlation and concordance were assessed using the Spearman and Cohen's Kappa coefficients, respectively. Positive percent agreement and negative percent agreement (NPA) with the VNT were also determined.

46 **Results:** The Wantai Total Ab assay targeting the receptor binding domain (RBD) within the 47 S protein presented the best sensitivity at different times during the course of disease. The 48 best correlation between antibody level and neutralizing antibody titer was found with the 49 Euroimmun S1-based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.61-0.79]). A 50 moderate concordance (Kappa [95%CI]: 0.43[0.23-0.63]) as well as the lowest NPA (33%) 51 was found between the Wantai Total Ab assay and the VNT. Compared to the Wantai Total 52 Ab assay, other total Ab or IgG assays targeting the S or the RBD (bioMérieux, DiaSorin, 53 Siemens,) were more concordant with the VNT (Kappa>0.7 for the three tests) and had a 54 higher NPA (range: 90% to 97%).

55 Conclusions: Although some assays presented a better concordance with VNT than others, 56 the present findings emphasize that commercialized serological tests including those targeting 57 the RBD cannot substitute VNT for the assessment of functional antibody response.

It is made available under a CC-BY-NC-ND 4.0 International license .

58 Introduction

59 The evaluation of the humoral immune response to SARS-CoV-2 with serological tests is 60 crucial to further manage the coronavirus disease 2019 (COVID-19) pandemic. Serological 61 testing represents an easy to implement and cost-effective method allowing to rapidly identify 62 individuals exposed to the virus [1,2]. Over the last few months, a large number of SARS-63 CoV-2 commercial assays have been evaluated for their ability to detect specific antibodies 64 [3–8]. However, the detection of specific SARS-CoV-2 antibodies does not indicate whether 65 or not the antibodies are functional for neutralizing the virus. In association with the 66 evaluation of other immune responses, such as cellular immunity, the determination of 67 neutralizing antibody titer is important to evaluate the protective immunity to SARS-CoV-2 68 after infection and therefore the risk of reinfection [9-11]. While the comparison of sensitivity 69 and specificity of serological tests has been increasingly studied, the association between the 70 results obtained with commercial tests and the virus neutralization test (VNT) has been 71 explored in only a few studies, and mostly among severe COVID-19 patients [12,13]. VNT is 72 considered as the reference to assess the functional ability of antibodies to block the entry of 73 the virus into human cells [14]. However, such an assay requires living virus manipulated in a 74 biosafety level 3 (BSL3) facility that needs trained staff and specific equipment, and which is 75 a tedious and time-consuming method. The first study exploring the association of 76 commercial serological assays and VNT claimed that the Wantai Total Ab assay detecting 77 total antibodies directed against the SARS-CoV-2 receptor binding domain (RBD) had the 78 best characteristics to detect functional antibodies at different stages and severity of disease 79 [12]. The RBD, within the sub-unit S1 of the spike protein, enables the viral entry into human 80 cells by fixing to the angiotensin-converting enzyme 2 (ACE2) receptor [15]. As emphasized 81 by the authors [12], there is an urgent need for further studies addressing the performance of

It is made available under a CC-BY-NC-ND 4.0 International license .

82 alternative high-throughput assays in correlation with neutralization among persons with mild

83 COVID-19.

84 Thus, the aim of the present study was to evaluate widely-used, high-throughputs tests in a

85 longitudinal cohort of mild COVID-19 patients by including the comparison with a VNT.

86 Methods

87 Study design and sample collection

88 A prospective longitudinal cohort study was conducted at the laboratory associated with the 89 National reference center for respiratory viruses (University Hospital of Lyon, France)[16]. 90 Healthcare workers (HCW) with symptoms suggesting a SARS-CoV-2 infection requiring a 91 reverse transcriptase (RT)-PCR test were included. Patients with a positive RT-PCR result at 92 inclusion (V1) returned weekly for 6 additional visits (V2-V7) for serum samples. Written 93 informed consent was obtained from all participants; ethics approval was obtained from the 94 national review board for biomedical research in April 2020 (Comité de Protection des 95 Personnes Sud Méditerranée I, Marseille, France; ID RCB 2020-A00932-37), and the study 96 was registered on ClinicalTrials.gov (NCT04341142). A total of 439 serum specimens were 97 longitudinally collected from 76 HCW; with the exception of one patient who required 98 hospitalization (not in intensive care unit), all of them developed mild forms of COVID-19. 99 Among the 439 collected samples, 170 of them taken at V2, V4, V7 from 56 patients were 100 tested by VNT.

101 Virological investigation

102 COVID-19 diagnosis for inclusion was performed by RT-PCR on nasopharyngeal swab using

103 the cobas® SARS-CoV-2 assay (Roche, Basel, Switzerland).

It is made available under a CC-BY-NC-ND 4.0 International license .

104 A total of 9 serological assays developed by leading global companies in the field (Abbott, 105 DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun) were investigated according 106 to the protocol recommended by each manufacturer (characteristics are summarized in Table 107 1). Positivity was established according to threshold value recommended by each 108 manufacturer. As previously suggested, we also evaluated a cut-off (OD ratio \geq 10) to 109 indicate the presence of protective antibodies for the Wantai Total Ab assay [12].

110 The VNT used for the detection and titration of neutralizing antibodies was performed as 111 previously described [17]. Briefly, a ten-fold dilution of each serum specimen in culture 112 medium (Dulbecco's Modified Eagle Medium containing antibiotics and 2% foetal calf 113 serum) was first heated for 30 min at 56°C to avoid complement-linked reduction of the viral 114 activity. Serial two-fold dilutions (tested in duplicate) of the serum specimens in culture 115 medium were mixed at equal volume with the live SARS-CoV2 virus. After gentle shaking 116 and a contact of 30 minutes at room temperature in plastic microplates, 150 μ L of the mix was 117 transferred into 96-well microplates covered with Vero E6 cells. The plates were incubated at 118 37° C in a 5% CO₂ atmosphere. The reading was evaluated microscopically 5 to 6 days later 119 when the cytopathic effect of the virus control reached 100 TCID₅₀/150 μ L. Neutralization 120 was recorded if more than 50% of the cells present in the well were preserved. The 121 neutralizing titer was expressed as the inverse of the higher serum dilution that exhibited 122 neutralizing activity; a threshold of 20 was used. All experiments were performed in a BSL3 123 laboratory. The comparison of this VNT with a standardized assay using retroviruses pseudo-124 typed with the SARS-CoV-2 S viral surface protein found a high correlation and concordance 125 [17].

126 Statistical analyses

It is made available under a CC-BY-NC-ND 4.0 International license .

127	For each test the clinical sensitivity was determined weekly after symptom onset. The
128	correlation and concordance with the VNT were assessed using the Spearman and Cohen's
129	Kappa coefficients, respectively. The concordance was classified as slight (Cohen's Kappa
130	coefficient, [0-0.2]), fair [0.21-0.4], moderate [0.41-0.6], substantial [0.61-0.8], and almost
131	perfect [0.81-1] according to Landis and Koch criteria. The positive and negative percentage
132	agreements (PPA, NPA) were also determined. The estimation of the correlation coefficient
133	was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad
134	assays. Specificity was assessed with 30 pre-pandemic serum specimens collected from
135	healthy donors in 2019. The estimates are given with their bilateral 95% confidence interval
136	(CI) calculated using the Wilson method. The 95% CI for Cohen's Kappa coefficient was
137	calculated using the bootstrap percentile method. The paired comparison of sensitivity
138	between two assays was performed with the non-parametric McNemar test. A p-value < 0.05
139	was considered as statistical significant.

It is made available under a CC-BY-NC-ND 4.0 International license .

140 **Results**

141 Sensitivity and specificity

142 During the first week after the onset of symptoms the sensitivity for the detection of 143 antibodies ranged from 6.6% (DiaSorin, Liaison) to 25.0% (Euroimmun). The second week 144 the sensitivity was greater than 70% for three tests including Bio-Rad, Wantai Total Ab, and 145 Euroimmun IgA assays (74.2%, 79.0% and 72.6%, respectively). The highest of sensitivity 146 was found at week # 3 for Bio-Rad (96.6%), Wantai Total Ab (100%), Wantai IgM (94.9%), 147 bioMérieux IgM (78.0%) and Euroimmun (96.6%), at week # 4 for Abbott (93.2%), and at 148 week # 6 for Diasorin (93.2%), Siemens (98.3%) and bioMérieux IgG (94.9%). After this 149 point, a decrease of sensitivity was noted for all assays except for the Wantai Total Ab which 150 remained steady at 100% over the course of the disease (Table 1). Compared to the Wantai 151 Total Ab assay, the differences were significant before 14 days post-symptom onset with all 152 other assays, except with the Euroimmun and Bio-Rad assays; after 14 days post-symptom 153 onset, the differences were significant with all other assays.

Regarding specificity, no false positive result was found using 30 pre-pandemic sera, although samples gave a borderline ratio (between 0.8 and 1.1) with the Euroimmun IgA assay (supplementary table 1).

157										
Manu (pla	ifacturer atform)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wan	itai	bioMe (Vid	érieux as®)	Euroimmun
Assa	ay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 lgG	SARS-CoV-2 Total	Platelia SARS- CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Ass	ay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Ar	ntigen	Ν	S1+S2	RBD	Ν	RBD	RBD	RBD	RBD	S1 =
Sensitivity v	vs SARS-CoV2 R	T-PCR [95%CI]								s ma
days after sy	mptom onset (n)									de a
[1-	7] (61)	9.84 [5.17-17.91]	6.56 [2.98-13.83]	6.56 [2.98-13.83]	18.03 [11.35-27.43]	22.95 [15.36-32.84]	13.11 [7.55-21.81]	8.20 [4.05-15.90]	11.48 [6.34-19.88]	25.00 [17.02-35
[8-1	[4] (63)	59.68 [49.23-69.31]	32.26 [23.41-42.59]	41.94 [32.18-52.37]	74.19 [64.18-82.19]	79.03 [69.41-86.23]	64.52 [54.11-73.71]	39.68 [30.17-50.04]	49.21 [39.09-59.38]	72.58 [62.47-80 81]
[15-:	21] (59)	91.53 [83.60-95.81]	83.05 [73.61-89.59]	89.83 [81.52-94.65]	96.61 [90.26-98.87]	100.00 [95.62-100.00]	94.92 [87.94-97.95]	86.44 [77.50-92.19]	77.97 [67.97-85.50]	96.61 [90.26-985287]
[22-:	28] (59)	93.22 [85.73-96.92]	86.44 [77.50-92.19]	93.22 [85.73-96.92]	94.92 [87.94-97.95]	100.00 [95.62-100.00]	89.83 [81.52-94.65]	93.22 [85.73-96.92]	69.49 [58.96-78.32]	91.53 [83.60-95 ⁰ 81]
[29-	35] (65)	86.15 [77.66-91.76]	92.31 [85.03-96.21]	93.85 [86.98-97.21]	92.19 [84.81-96.15]	100.00 [96.00-100.00]	84.62 [75.89-90.58]	90.77 [83.13-95.15]	52.31 [42.23-62.20]	84.62 [75.89-90
[36-	42] (59)	89.83 [81.52-94.65]	93.22 [85.73-96.92]	98.31 [92.75-99.62]	91.53 [83.60-95.81]	100.00 [95.62-100.00]	88.14 [79.49-93.44]	94.92 [87.94-97.95]	45.76 [35.51-56.38]	88.14 [79.49-9344]
[43-	85] (73)	89.04 [81.58-93.71]	89.04 [81.58-93.71]	95.89 [90.15-98.35]	88.89 [81.34-93.62]	100.00 [96.38-100.00]	81.94 [73.38-88.20]	87.67 [79.97-92.68]	43.84 [34.67-53.44]	79.45 [70.69-86, 1]
158										N N N N N N N N N N N N N N N N N N N
159	Table 1 –	Sensitivity of the	he serological a	assays was dete	ermined by corr	paring the outco	ome to positive	SARS-CoV-2	PCR. Positivity	was ^{4.0} Inter
160	established	according to th	reshold value	recommended b	y each manufa	cturer. Ab: antib	odies, Ig: immu	noglobulin, EL	ISA: enzyme-li	nked at
161	161 immunosorbent assay, CMIA: chemiluminescence microparticule immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-									
162	linked	fluorescent	assay,	n:	number	of samp	oles, CI:	confide	ence inte	erval.

It is made available under a CC-BY-NC-ND 4.0 International license .

163 Kinetics of neutralizing antibody titers

The neutralizing capacity of antibodies was determined at three time points for 56 patients (n=170 samples). No neutralizing antibody was detected in 42.0% (21/50), 5.8% (3/51), and 8.7% (6/69) of samples collected between, respectively, 1-14, 15-28, and more than 28 days after symptom onset. For the samples with a detection of neutralizing antibody, the median [IQR] titer was 60[40-100] between 1-14 days post symptom, reached 80[60-120] between 15-28 days post symptom and decreased in samples collected after more than 28 days (median: 60[40-120]).

171 Comparison of results between commercial kits and VNT

172 The best correlation between commercial kits and VNA was found with the Euroimmun S1-

based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.61-0.79]) while the Abbott N-based

assay presented the lowest correlation (0.46 [0.32-0.59]; Figure 1, Table 2).

A slight and fair concordance with VNT were noticed for the 2 IgM assays evaluated herein (Kappa [95%CI]: 0.24 [0.14-0.36] for bioMérieux IgM and 0.40 [0.21-0.58] for the Wantai IgM assays). Regarding total Ab or IgG assays targeting the S protein, three had substantial concordance with VNT (Kappa [95%CI]: 0.71 for bioMérieux [0.57-0.84], 0.70 [0.56-0.83] for DiaSorin, and 0.72 [0.55-0.85] for Siemens assays) while the concordance with the Wantai Total Ab assay was moderate (0.43[0.23-0.63]; Table 2).

For the Wantai Total Ab assay, 20/30 samples with no neutralizing antibody had a positive Wantai Total Ab; 18 these had an OD ratio < 10. Of note, 9/30 samples were collected more than 14 days post symptom onset. Regarding the samples with an OD ratio < 10 with the Wantai Total ab assay (39/140, 28%), all had a low level of neutralizing antibodies (range: 20-50; Figure 1).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 186 The NPA ranged from 33.3% [21.1-48.3] for the Wantai Total Ab assay to 96.8% for the
- 187 DiaSorin and was < 90% for 7/9 assays. The PPA was > 90% for all tests except the DiaSorin
- and the two IgM based assays (Wantai and bioMérieux) (Table 2).

Manufact (platfor	urer m) Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai		bioMérieux (Vidas®)		Euroimmun
Assay na	me SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV- 2Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay ty	pe CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antiger	n N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1
Concordanc	e with virus VNT - Cohen's K	appa coefficient [95%	CI]						It is
Overall (n=	170) 0.64 [0.49-0.79]	0.70 [0.56-0.83]	0.72 [0.55-0.85]	0.62 [0.44-0.76]	0.43 [0.23-0.63]	0.40 [0.21-0.58]	0.71 [0.57-0.84]	0.24 [0.14-0.36]	0.61 [0.43-0.76] a
<14 dp	s 0.70 [0.45-0.88]	0.41 [0.19-0.60]	0.68 [0.45-0.84]	0.69 [0.45-0.86]	0.46 [0.21-0.67]	0.61 [0.35-0.79]	0.41 [0.29-0.76]	0.52 [0.27-0.72]	0.60 [0.35-0.79] a
>14 dp	s 0.40 [-0.06-0.72]	0.86 [0.65-1]	0.51 [0-0.89]	0.45 [-0.05-0.79]	NA	0.08 [-0.09-0.35]	0.90 [0.71-1.00]	0.18 [0.02-0.25]	0.55 [0.06-0.81] ali
Correlation	Correlation between Ab level and neutralizing Ab titer								
Spearm coefficient [9	an 0.46 [0.32-0.59]	0.52 [0.38-0.64]	NA	NA	0.56 [0.43-0.66]	0.52 [0.38-0.64]	0.60 [0.48-0.71]	0.50 [0.31-0.65]	0.71 [0.61-0.79] der
Negative an	Negative and Positive Percent Agreement with VNT								
NPA[95%	5CI] 74.2 [59.7-84.8]	96.8 [86.8-99.3]	80.7 [66.7-89.7]	61.3 [46.6-74.2]	33.3 [21.1-48.3]	56.7 [41.9-70.4]	90.3 [78.1-96.1]	83.9 [70.4-91.9]	67.7 [53.0-79.6]
PPA[95%	92.1 [87.6-95.1]	87.9 [82.6-91.7]	93.6 [89.3-96.2]	95.7 [91.9-97.8]	99.3 [96.9-99.9]	86.4 [81.0-90.5]	90.1 [85.1-93.5]	57.4 [50.5-64.1]	92.9 [88.4-95.7]
107 Table 2 – Comparison between serological assays and virus neutralization test. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked 190 Table 2 – Comparison between serological assays and virus neutralization test. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked 191 immunosorbent assay, CMIA: chemiluminescence microparticule immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-linked 192 linked fluorescent assay, n: number of samples, CI: confidence interval, dps: days post onset of symptoms, test. VNT: Virus neutralization test. 193 The estimation of the correlation coefficient was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad 194 assays. The Cohen's Kappa coefficient after 14 days post symptom onset cannot be interpreted for the Wantai Total Ab assay because the									
195 s	95 sensitivity of this test was 100%.								

It is made available under a CC-BY-NC-ND 4.0 International license .

196 **Discussion**

In a longitudinal study of 76 HCW with RT-PCR-confirmed COVID-19, we found that the Wantai Total Ab assay had the best sensitivity over the course of the disease. In particular, the sensitivity reached and remained at 100% as soon as week # 3 post symptom onset. This finding observed in mild COVID-19 patients is consistent with previous reports of excellent sensitivity of this test notably in severe patients [3,12].

202 In addition to sensitivity, the ability of a commercial test to evaluate the protective immunity 203 needs to be assessed. With this aim, Tang et al. compared three commercial assays (Roche 204 Total Ab, Abbott IgG, both tests targeting the N protein, and Euroimmun IgG assays targeting 205 the S protein) to VNT on 67 specimens [13]. The NPA of these tests was poor, ranging from 206 56% for Roche to 81% for Euroimmun, making them imperfect proxies for neutralization. 207 These findings are highly consistent with those of the present study that found a NPA below 208 90% for all tests except for bioMérieux IgG and DiaSorin. In contrast, it is interesting to note 209 that the Wantai Total Ab had the lowest NPA (33%). Furthermore, the concordance between 210 VNT and the Wantai Total Ab assay was only moderate while the concordance was 211 substantial with bioMérieux IgG, DiaSorin, Siemens, Abbott, Euroimmun and Bio-Rad. The 212 low NPA and moderate concordance noticed for the Wantai Total Ab might be partially 213 explained by the excellent ability of this test to detect RBD-specific antibodies at the very 214 early phase of infection, irrespective of their neutralizing properties in line with the delay 215 required for antibody maturation [18]. In the first study comparing VNT with commercialized 216 tests, the authors found that the Wantai Total Ab assay had the best characteristics to detect 217 functional antibodies in different stages and severity of disease [12]. However the median 218 interval between the onset of symptoms and sample collection was 43 days for mild patients 219 (n=71 samples) and thus the antibodies could be detected with both the Wantai Total Ab and

It is made available under a CC-BY-NC-ND 4.0 International license .

the VNT assay at this time. As the authors used VNT as the gold-standard for sensitivity

assessment, this explains the difference in findings with the present study [12].

Importantly, as previously reported by others [18,19], not all RBD-binding antibodies have neutralizing properties which is consistent with that reported herein regarding the RBD-based assays that do not have perfect concordance with VNT. Conversely, serological assays targeting a region other than the S protein may be associated with functional information, as previously reported [14,20–22]. In the present study, the Abbott and Bio-Rad assays directed against the N protein presented a substantial concordance with VNT as N-directed and RBDneutralizing antibodies can be produced concomitantly over the course of the disease.

In addition to the different targeted antigens, the heterogeneity in assay performance found herein could also be explained by various factors including the detected isotypes. Moreover, antibody levels may also be very different according to the time since symptom onset and according to clinical severity of the disease [23]. Herein, serum samples were collected longitudinally from disease diagnosis enabling to explore the early phase of the antibody response in a cohort of HCW with mild symptoms, which constitutes one of the main strength of the present study.

236 The present study does, however, have certain limitations. For instance, specificity was not 237 been extensively studied; yet the Euroimmun IgA assay seemed to have the worst specificity, 238 which is consistent with previous studies reporting a lack of specificity for this assay [5,6,12]. 239 In addition, the performance of other notable commercial assays such as Euroimmun IgG or 240 Roche Ig Total were not assessed. Second, not all the samples were systematically tested by 241 VNT, in-line with the labor-intensive nature of this method. Finally, the size of the tested 242 population remains small, which limits the extrapolation of the results, although the present 243 study represents the largest one comparing VNT to other serological tests through a 244 longitudinal design.

It is made available under a CC-BY-NC-ND 4.0 International license .

245 The results presented herein obtained from mild COVID-19 patients confirm that, for 246 exposure assessment, the Wantai Total Ab assay should be preferred to other commercial kits 247 due to a very high sensitivity. For evaluating protective immunity, the Wantai Total Ab assay 248 with an optimized cut-off or other tests targeting the S protein as Euroimmun, DiaSorin or 249 bioMérieux IgG could be more useful, notably to screen serum specimens candidate for the 250 presence of neutralizing antibodies. However, these tests or others cannot substitute a VNT 251 for assessing functional antibody response; neutralizing assays remain the gold standard and 252 easy-to-use tests, such as those based on pseudoviruses [6,17,24], should be developed and 253 standardized. Furthermore, the recent development of surrogate virus neutralization tests 254 based on antibody-mediated blockage of the interaction between ACE-2 receptor and the 255 RBD is very promising as they were designed in an ELISA format enabling high-throughput 256 testing [19,25].

In conclusion, the present study provides original data concerning the performance of widelyused serological tests, which could help diagnostic laboratories in the choice of a particular

250 used scrological tests, which could help diagnostic haboratories in the choice of a particular

259	assay	according	to	the	intended	use.
-----	-------	-----------	----	-----	----------	------

It is made available under a CC-BY-NC-ND 4.0 International license .

260 Figure 1 legend

261 Correlation of SARS-CoV-2 neutralizing antibody titers tested by a virus neutralization test to 262 antibodies level measured by selected assays. (A) bioMérieux IgM (B) Wantai IgM (C) 263 Euroimmun IgA (D) Wantai total Ab (E) bioMérieux IgG (F) Abbott (G) DiaSorin IgG. 264 Magenta dots indicate patient specimen collected ≤ 14 days post onset of symptoms (dps), 265 orange dots indicate samples collected from 14-28 dps, green dots indicate specimen collected 266 more than 28 dps. Dotted lines indicate the cut-off for positivity of each assay, as indicated by 267 the manufacturer: Wantai, Abbott, bioMérieux, Euroimmun, OD ratio > 1; DiaSorin >12 268 AU/ml. OD: optical density.

269 COVID-SER study group

270 Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent, 271 Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello 272 Pierre, Cotte Laurent, d'Aubarede Constance, Durupt François, Escuret Vanessa, Fascia 273 Pascal, Fassier Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre, 274 Gillet Myriam, Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence, 275 Lahousse Matthieu, Lina Bruno, Lozano Hélène, Makhloufi Djamila, Massardier-Pilonchéry 276 Amélie, Milon Marie-Paule, Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-277 Anne, Oria Fatima, Paul Adèle, Perry Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud 278 Muriel, Samperiz Audrey, Schlienger Isabelle, Simon Chantal, Trabaud Mary-Anne, 279 Trouillet-Assant Sophie

280 Acknowledgements

We thank all the personnel of the occupational health and medicine department of Hospices Civils de Lyon who contributed to the samples collection. We thank Lucie Charreton and Khadija Sfouli for their excellent work concerning serological testing, all the technicians from the virology laboratory whose work made it possible to obtain all these data, as well as Amira

It is made available under a CC-BY-NC-ND 4.0 International license .

285 Lachekhab and Naima Rolnin for their technical assistance. We thank Karima Brahima and

all members of the clinical research and innovation department for their reactivity (DRCI,

287 Hospices Civils de Lyon). We thank Philip Robinson (DRCI, Hospices Civils de Lyon) for

- 288 his help in manuscript preparation.
- 289 Author contributor's statement

290 All authors were involved in the analysis and interpretation of data as well as drafting the 291 manuscript or revising it critically for important intellectual content. AB, BP, VP, FG, JBF 292 and STA made substantial contributions to the conception and design of the study and 293 designed the experiments. BP performed VNT. MAT and VE performed the serological assay 294 experiments. NG, AP, CA, AMP, AB, and JBF were involved in patient care, VP performed 295 the data collection, STA, AB, MA and BP performed the data analysis. MR and CLJ 296 performed the statistical analysis. AB and STA wrote the paper, BL, BP, JBF, AP, VE and 297 MAT revised the manuscript content. All authors read and approved the final manuscript.

298 Conflict interests statement

Antonin Bal has received grant from bioMérieux and has served as consultant for bioMérieux for work and research not related to this manuscript. Sophie Trouillet-Assant has received research grant from bioMérieux concerning previous works not related to this manuscript. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

305 Funding

This research is being supported by Hospices Civils de Lyon and by Fondation des HospicesCivils de Lyon.

It is made available under a CC-BY-NC-ND 4.0 International license .

308 **References**

309	[1]	Krammer F, Simon V. Serology assays to manage COVID-19. Science 2020;368:1060–
310		1. https://doi.org/10.1126/science.abc1227.
311	[2]	Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet
312		Infect Dis 2020;20:758–9. https://doi.org/10.1016/S1473-3099(20)30322-4.
313	[3]	Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. Comparison of eight
314		commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG
315		or total antibody. J Clin Virol 2020;132:104613.
316		https://doi.org/10.1016/j.jcv.2020.104613.
317	[4]	Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E,
318		Vandecandelaere P, et al. Antibody response against SARS-CoV-2 spike protein and
319		nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs. Clin Microbiol
320		Infect 2020. https://doi.org/10.1016/j.cmi.2020.07.038.
321	[5]	Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al.
322		Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun
323		IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect 2020;26:1082–7.
324		https://doi.org/10.1016/j.cmi.2020.05.023.
325	[6]	Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a
326		commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect
327		2020. https://doi.org/10.1016/j.cmi.2020.06.024.
328	[7]	Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four High-
329		Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J
330		Clin Microbiol 2020;58. https://doi.org/10.1128/JCM.01243-20.
331	[8]	Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al.
332		Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
333		analysis. BMJ 2020;370:m2516. https://doi.org/10.1136/bmj.m2516.
334	[9]	Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al.
335		Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
336		fishery vessel outbreak with high attack rate. MedRxiv 2020:2020.08.13.20173161.
337		https://doi.org/10.1101/2020.08.13.20173161.
338	[10]	Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function,
339		durability, and role in protection. Sci Immunol 2020;5.
340		https://doi.org/10.1126/sciimmunol.abd6160.
341	[11]	Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et
342		al. A systematic review of antibody mediated immunity to coronaviruses: kinetics,
343		correlates of protection, and association with severity. Nat Commun 2020;11:4704.
344		https://doi.org/10.1038/s41467-020-18450-4.
345	[12]	GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et
346		al. An evaluation of COVID-19 serological assays informs future diagnostics and
347		exposure assessment. Nat Commun 2020;11:3436. https://doi.org/10.1038/s41467-020-
348		17317-у.
349	[13]	Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al.
350		Association between SARS-CoV-2 neutralizing antibodies and commercial serological
351	FA	assays. Clin Chem 2020. https://doi.org/10.1093/clinchem/hvaa211.
352	[14]	Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other
353		Human Coronaviruses. Trends Immunol 2020;41:355–9.
1 5 /1		

354 https://doi.org/10.1016/j.it.2020.03.007.

355 356 357	[15]	Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. https://doi.org/10.1038/s41586-020-2012-7
358	[16]	Trouillet-Assant et al. Assessment of Serological Techniques for Screening Patients
359	[10]	Regarding COVID-19 (COVID-SER): a prospective multicentric study BMI open
360		2020 In press n d
361	[17]	Legros V Denolly S Vogrig M Boson B Rigaill I Pillet S et al. A longitudinal study
362	[1,]	of SARS-CoV-2 infected patients shows high correlation between neutralizing
363		antibodies and COVID-19 severity. MedRxiv 2020:2020.08.27.20182493.
364		https://doi.org/10.1101/2020.08.27.20182493.
365	[18]	Ju B. Zhang O. Ge J. Wang R. Sun J. Ge X. et al. Human neutralizing antibodies elicited
366		by SARS-CoV-2 infection. Nature 2020;584:115–9. https://doi.org/10.1038/s41586-020-
367		2380-z.
368	[19]	Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate
369		virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-
370		protein interaction. Nat Biotechnol 2020;38:1073-8. https://doi.org/10.1038/s41587-
371		020-0631-z.
372	[20]	Tong P-B-V, Lin L-Y, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies
373		help? Life Sci 2020;255:117836. https://doi.org/10.1016/j.lfs.2020.117836.
374	[21]	Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
375		Antib Ther 2020;3:109–14. https://doi.org/10.1093/abt/tbaa009.
376	[22]	Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies:
377		implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin
378		Immunother 2020:1–4. https://doi.org/10.1080/21645515.2020.1787074.
379	[23]	Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
380		Differences in antibody kinetics and functionality between severe and mild SARS-CoV-
381		2 infections. J Infect Dis 2020. https://doi.org/10.1093/infdis/jiaa463.
382	[24]	Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a
383		pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 2020;9:680-
384		6. https://doi.org/10.1080/22221751.2020.1743767.
385	[25]	Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, et al. A SARS-CoV-2
386		serological assay to determine the presence of blocking antibodies that compete for
387		human ACE2 binding. MedRxiv 2020. https://doi.org/10.1101/2020.05.27.20114652.
200		

